Last reviewed · How we verify
IHL-42X High Dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
IHL-42X High Dose (IHL-42X High Dose) — Incannex Healthcare Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IHL-42X High Dose TARGET | IHL-42X High Dose | Incannex Healthcare Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IHL-42X High Dose CI watch — RSS
- IHL-42X High Dose CI watch — Atom
- IHL-42X High Dose CI watch — JSON
- IHL-42X High Dose alone — RSS
Cite this brief
Drug Landscape (2026). IHL-42X High Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/ihl-42x-high-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing